Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2025

Genmab — Februar 2025

Planlagt Fastgjort Låst Flyttet Genmab
699 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #421

    Royalties from Darzalex are providing ample cash flow, as the company works to develop its pipeline
    and prioritize commercialization efforts for Epkinly/Tepkinly (codeveloped with wide-moat AbbVie),
    which has received regulatory approvals for the treatment of diffuse large B-cell lymphoma and
    follicular lymphoma in several markets, including the United States, Europe, and Japan. Epkinly has had
    a strong launch, and it generated DKK 1.7 billion in net product sales in the US and Japan in 2024.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #422

      We
      forecast Epkinly/Tepkinly to be on track to generate over DKK 10 billion in sales toward the end of our
      10-year forecast period.
      During the year, Genmab ’ s operating expenses increased 24% compared with 2023, reflecting
      investments in Genmab ’ s pipeline, postlaunch expenses for Epkinly, and profit-sharing commitments to AbbVie related to Epkinly sales. While these investments should contribute to future growth, cost
      management will be important in the longer term to drive operating margins.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #423

        We like that Genmab ’ s acquisition of Profound Bio gives it worldwide rights to three antibody-drug
        conjugate candidates in clinical development, led by Rina-S, which is enrolling patients in its phase 3
        ovarian cancer trial. We assign Rina-S a 40% probability of approval in our base case, and we think it
        could reach the market as early as 2027.

        1 Reply Last reply
        0
        • R Offline
          R Offline
          Raun
          wrote on sidst redigeret af
          #424

          Thanks EL.... Fair Value 2650dkr 🙂

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #425

            Det må vel være uden Hexa?

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #426

              Ja. En lille krølle er i øvrigt, at det er rigtigt, at Dara udgør 80% af lige præcis royalties, men Genmab tjener også på (salg og milestones etc.)

              1 Reply Last reply
              0
              • A Offline
                A Offline
                Aaanditsgone
                wrote on sidst redigeret af
                #427

                Darzalex udgjorde 65% af omsætningen i 2024

                1 Reply Last reply
                0
                • A Offline
                  A Offline
                  Aaanditsgone
                  wrote on sidst redigeret af
                  #428

                  I øvrigt faldet støt fra 82% i 2021.

                  1 Reply Last reply
                  0
                  • HenrikhotH Offline
                    HenrikhotH Offline
                    Henrikhot
                    wrote on sidst redigeret af
                    #429

                    Jeg prøvede lige at sammenligne Darzelex andel af omsætningen de sidste 5 år. https://proinvestor.com/boards/124771/

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #430

                      https://seekingalpha.com/article/4758476-genmab-a-s-gmab-q4-2024-earnings-conference-call-transcript Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bikube
                        wrote on sidst redigeret af
                        #431

                        Kursen sluttede 10 kr højere i U S 1514,40.

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #432

                          Blandt de aktier, der har stor indflydelse på indeksene, er Nvidia, som steg 2,6 procent til 138,85 dollar pr. Tesla er stort set uændret og handles til $355,84 per aktie. Apple er også i grønt for dagen, en stigning på 1,3 procent til $244,60 per aktie. På listen over aktier med den højeste handelsvolumen finder vi halvlederproducenten Super Micro Computers, som steg markant med 13,5 procent til 48,00 USD pr.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #433

                            J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27 (Japan) https://pj.jiho.jp/article/252495

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #434

                              InnovaTV 205 Completion dates extended by > 1 year ; i can only imagine this being done to capture longer Overal Survival in the data than previously anticipated?
                              they stopped recruiting Jan23 https://clinicaltrials.gov/study/NCT03786081?tab=history&a=25&b=26&compareMode=sideBySide#version-content-panel

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #435

                                Teknisk: Genmab løftes yderligere i USA efter dansk lukketid, trendvending på vej efter halvering de seneste år? https://proinvestor.com/investornyt/1278893/teknisk-genmab-loftes-yderligere-i-usa-efter-dansk-lukketid-trendvending-pa-vej-efter-halvering-de-seneste-ar

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #436

                                  Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3588

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #437

                                    Genmab/Deutsche Bank: Kursmålet sænkes til 2100 kr. fra 2250 kr. - "køb" gentages https://proinvestor.com/investornyt/1279192/genmab-deutsche-bank-kursmalet-saenkes-til-2100-kr-fra-2250-kr-kob-gentages

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #438

                                      Genmab - 2 neglebider uger med stor betydning https://proinvestor.com/boards/124798

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #439

                                        Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma https://www.healio.com/news/hematology-oncology/20250212/regimen-may-become-new-standard-for-relapsedrefractory-diffuse-large-bcell-lymphoma

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #440

                                          “We expected the clinical outcomes to be good but were surprised about how good they were,” Joshua D. Brody, MD, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, told Healio. “CD20xCD3 bispecific antibodies plus Gem-Ox will likely become a new standard of care for patients with relapsed/refractory DLCBL.”

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper